Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-world data shows REBYOTA™ may stop c. diff from coming back

NCT ID NCT05835219

Prevention Sponsor: Ferring Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This observational study followed 145 adults who received REBYOTA™ to prevent another Clostridioides difficile infection (CDI) after completing antibiotics. Researchers collected information from medical records over 6 months to see how many people stayed infection-free. The goal was to understand how well the treatment works in everyday medical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

145 people

The number who actually took part.

Started

Jun 2023

Finished

Aug 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Subjects who have received antibiotic treatment for Clostridioides Difficile Infection

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Signed and dated informed consent form (ICF) * Age ≥ 18 years * Diagnosis of rCDI as determined by the treating physician * Completed antibiotic treatment for the presenting rCDI episode * Prescription for REBYOTA™ to prevent rCDI according to the approved indication Exclusion Criteria: * Currently enrolled in an interventional clinical trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Recurrence of clostridium difficile infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Clostridium difficile colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Recurrence of clostridium difficile infection

Contacts and locations

Locations

  • Ferrin Investigational Site

    Atlanta, Georgia, 30322, United States

  • Ferring Investigational Site

    Chandler, Arizona, 85224, United States

  • Ferring Investigational Site

    Chula Vista, California, 91910, United States

  • Ferring Investigational Site

    Murrieta, California, 92563, United States

  • Ferring Investigational Site

    Oceanside, California, 92054, United States

  • Ferring Investigational Site

    Sacramento, California, 95816, United States

  • Ferring Investigational Site

    Hamden, Connecticut, 06518, United States

  • Ferring Investigational Site

    Gainesville, Florida, 32610, United States

  • Ferring Investigational Site

    Orlando, Florida, 32806, United States

  • Ferring Investigational Site

    Port Orange, Florida, 32127, United States

  • Ferring Investigational Site

    Tampa, Florida, 33614, United States

  • Ferring Investigational Site

    Zephyrhills, Florida, 33542, United States

  • Ferring Investigational Site

    La Grange, Georgia, 30240, United States

  • Ferring Investigational Site

    Savannah, Georgia, 31405, United States

  • Ferring Investigational Site

    Burr Ridge, Illinois, 60527, United States

  • Ferring Investigational Site

    Maywood, Illinois, 60153, United States

  • Ferring Investigational Site

    Iowa City, Iowa, 52242, United States

  • Ferring Investigational Site

    Wichita, Kansas, 67211, United States

  • Ferring Investigational Site

    Jefferson, Louisiana, 70121, United States

  • Ferring Investigational Site

    Boston, Massachusetts, 02115, United States

  • Ferring Investigational Site

    Worcester, Massachusetts, 01608, United States

  • Ferring Investigational Site

    Detroit, Michigan, 48201, United States

  • Ferring Investigational Site

    Detroit, Michigan, 48202, United States

  • Ferring Investigational Site

    Farmington Hills, Michigan, 48336, United States

  • Ferring Investigational Site

    Omaha, Nebraska, 68198, United States

  • Ferring Investigational Site

    Teaneck, New Jersey, 07666, United States

  • Ferring Investigational Site

    New York, New York, 10016, United States

  • Ferring Investigational Site

    New York, New York, 10021, United States

  • Ferring Investigational Site

    New York, New York, 10279, United States

  • Ferring Investigational Site

    Rochester, New York, 14618, United States

  • Ferring Investigational Site

    Stony Brook, New York, 11794, United States

  • Ferring Investigational Site

    Fargo, North Dakota, 58122, United States

  • Ferring Investigational Site

    Cincinnati, Ohio, 45267, United States

  • Ferring Investigational Site

    Middleburg Heights, Ohio, 44130, United States

  • Ferring Investigational Site

    DuBois, Pennsylvania, 15801, United States

  • Ferring Investigational Site

    Pittsburgh, Pennsylvania, 15237, United States

  • Ferring Investigational Site

    Charleston, South Carolina, 29425, United States

  • Ferring Investigational Site

    Knoxville, Tennessee, 37909, United States

  • Ferring Investigational Site

    Dallas, Texas, 75246, United States

  • Ferring Investigational Site

    Houston, Texas, 77030, United States

  • Ferring Investigational Site

    West Jordan, Utah, 84088, United States

  • Ferring Investigational Site

    Charlottesville, Virginia, 22903, United States